Why Celgene's Acquisition Of Juno Matters For Biotech And Investors

Jan 23, 2018, 10:20 AM by Michael Croft

Forbes | Celgene just acquired immunotherapy biotech Juno Therapeutics in a $9 billion dollar deal. The deal will allow Celgene to compete in a space already occupied by Novartis and Gilead as they vie for hegemony in a new field of oncology.

January 23, 2018 | Celgene just acquired immunotherapy biotech Juno Therapeutics in a $9 billion dollar deal. The deal will allow Celgene to compete in a space already occupied by Novartis and Gilead as they vie for hegemony in a new field of oncology. Forbes